← Leaderboards
Edmund J Gosselin
Albany Medical College
$7,026,633
Attributed
$9,101,183
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2007–19$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$9,101,183 · 9
By mechanism
R01$4,456,248 · 2
P01$2,891,232 · 3
R21$1,753,703 · 4
Top collaborators
- Karsten R.O. Hazlett5 shared
- Timothy J Sellati4 shared
- Xiaoping Zhu2 shared
Most similar at Albany Medical College
Same institution · by research overlap
- Dennis W. Metzger$14,084,897
- Karsten R.o. Hazlett$3,136,768
- Douglas Scott Reed$2,392,313
- Eileen M. Barry$25,546,080
- Chandra Shekhar Bakshi$1,543,222
Others in their field
Top investigators on “Antigens”
- Barton F Haynes · Duke University$488,918,563
- Lawrence Corey · Fred Hutchinson Cancer Center$325,880,100
- Dennis R. Burton · Scripps Research Institute$291,395,948
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$245,204,950
- Jeffrey P Krischer · University Of South Florida$208,289,343
- Dan H. Barouch · Fred Hutchinson Cancer Center$124,506,327
Research focus
AntigensFrancisella TularensisCellsPathogenInfectionImmune ResponseMediatingVaccinesVaccine DevelopmentImmuneIn VivoGenerationsCytokineBaseProductionMonitorIn VitroAntigen TargetingB-LymphocytesT-LymphocyteAdjuvantComplexPathogenesisResponse
Grant awards (26)
Development of an adjuvant-free mucosal vaccine platform via sequential FcRn-mediated transepithelial Ag transport to the NALT and Fc RI-enhanced Ag processing and presentation within the NALT.$197,813
R21 · FY2019 · AI · contact PI
Development of an adjuvant-free mucosal vaccine platform via sequential FcRn-mediated transepithelial Ag transport to the NALT and Fc RI-enhanced Ag processing and presentation within the NALT.$252,563
R21 · FY2018 · AI · contact PI
Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC-Targeting$584,009
R01 · FY2017 · AI · contact PI
Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC-Targeting$584,009
R01 · FY2016 · AI · contact PI
Redox Control of F. tularensis Pathogenesis$427,997
P01 · FY2016 · AI · contact PI
Immunology Core$221,415
P01 · FY2016 · AI · contact PI
An Adjuvant-Independent Dual-Targeted (Multi-Function) Mucosal Vaccine Platform$197,500
R21 · FY2016 · AI · contact PI
Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC-Targeting$584,009
R01 · FY2015 · AI · contact PI
Redox Control of F. tularensis Pathogenesis$377,431
P01 · FY2015 · AI · contact PI
An Adjuvant-Independent Dual-Targeted (Multi-Function) Mucosal Vaccine Platform$218,846
R21 · FY2015 · AI · contact PI
Immunology Core$209,761
P01 · FY2015 · AI · contact PI
Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC-Targeting$584,009
R01 · FY2014 · AI · contact PI
Redox Control of F. tularensis Pathogenesis$425,479
P01 · FY2014 · AI · contact PI
Immunology Core$214,340
P01 · FY2014 · AI · contact PI
Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC-Targeting$584,009
R01 · FY2013 · AI · contact PI
Redox Control of F. tularensis Pathogenesis$436,432
P01 · FY2013 · AI · contact PI
Immunology Core$237,673
P01 · FY2013 · AI · contact PI
Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination$384,689
R01 · FY2012 · AI · contact PI
Immunology Core$340,704
P01 · FY2012 · AI · contact PI
Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination$384,689
R01 · FY2011 · AI · contact PI
Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination$388,575
R01 · FY2010 · AI · contact PI
Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination$378,250
R01 · FY2009 · AI · contact PI
Protective Activity of a Multi-Functional Immunogen$224,481
R21 · FY2008 · AI · contact PI
Protective Activity of a Multi-Functional Immunogen$197,500
R21 · FY2007 · AI · contact PI
ENHANCED T AND B CELL RESPONSES VIA RECOMBINANT PROTEINS$232,500
R21 · FY2001 · AI
ENHANCED T AND B CELL RESPONSES VIA RECOMBINANT PROTEINS$232,500
R21 · FY2000 · AI